Tag: IMU-935

IMU-935 is less effective than a placebo, Immunic shares plummet

ADC评论 October 22, 2022

On October 20, Immunic announced that its Phase Ib clinical trial of its RORγt inverse agonist IMU-935 in the treatment of psoriasis failed to meet

Latest Articles

azide peg linker click chemistry

Leveraging Azide PEG in Biopharmaceuticals: Uniting Azide Linkers and Click Chemistry

October 20, 2023

peg-tco

TCO-Functionalized PEG Derivatives: Versatile Tools for Bioconjugation

October 16, 2023

Tetrazine PEG

Tetrazine and Methyltetrazine: Structural Distinctions and Their Roles in Pharmaceutical Research

October 8, 2023

endo bcn, exo bcn, bcn peg

BCN Compounds in Pharmaceutical Research and Development

October 6, 2023

cydyes

An Overview of Cyanine Dyes: Types, Wavelengths, and Applications Across Industries

September 19, 2023

Protein Conjugation

Unveiling the Power of Protein Conjugation: The Biochemical Game Changer

May 26, 2023

Hot Articles

Leveraging Azide PEG in Biopharmaceuticals: Uniting Azide Linkers and Click Chemistry

October 20, 2023

Tetrazine and Methyltetrazine: Structural Distinctions and Their Roles in Pharmaceutical Research

October 8, 2023

TCO-Functionalized PEG Derivatives: Versatile Tools for Bioconjugation

October 16, 2023

BCN Compounds in Pharmaceutical Research and Development

October 6, 2023